Gilead Sciences, Inc.

333 Lakeside Drive,
Foster City, California 94404
United States,
(650) 574-3000
www.gilead.com

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences, Inc. was formed in 1987 and is headquartered in Foster City, California.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.8/yr) # 11 1 - 2 1 - 15
vol $17.2B $510M $535M $400M $18.6B
Sell (0.2/yr) # 2 - - - - 1 3
vol $206M $206M
  18

Top M&A Advisors

Financial Deals
Sign-up to View
2
Sign-up to View
2
Sign-up to View
1
Legal Deals
Sign-up to View
1
Sign-up to View
1
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Pharmasset, Inc.
$11.0B (2012-01-17)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Gilead Oncology Business
$200M (2001-12-21)

According to our data here at Mergr, Gilead Sciences has acquired 16 companies, including 4 in the last 5 years. A total of 4 acquisitions came from private equity firms. It has also divested 3 assets.

Gilead Sciences’ largest acquisition to date was in 2012, when it acquired Pharmasset for $11.0B. It’s largest disclosed sale occurred in 2001, when it sold Gilead Oncology Business to OSI Pharmaceuticals for $200M. Gilead Sciences has acquired in 7 different US states, and 5 countries. The Company’s most targeted sectors include life science (94%) and chemicals (7%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 419 life science companies that have made at least 1 acquisition, 25 have acquired at least 5 companies, and 4 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 24 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Gilead Sciences’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.1K Private Equity Firms
  • 110K M&A Transactions
  • 120K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.